EU Expansion Approval for Reblozyl - Major Move for Bristol Myers
Wednesday, 3 April 2024, 17:07
EU Approval Expansion for Reblozyl
The European Union has granted approval for the expanded use of Reblozyl, an anemia therapy drug developed by Bristol Myers and Merck. The approval now includes treatment for adults with myelodysplastic syndromes, a critical development in the field of hematology.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.